Noom is a legitimate digital weight loss program built around food logging, lessons, coaching, and behavior change. Some Noom plans also include access to prescription weight loss medications for eligible patients. It is not the same as Ozempic; Ozempic is semaglutide, while Noom is a program that may support lifestyle change and medication access.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What is the Noom weight loss program?
Noom is an app-based weight management program that uses daily lessons, food logging, weigh-ins, activity tracking, and coaching to help people build habits that support a calorie deficit. In a published Noom trial protocol, 600 participants were randomized to a Noom Healthy Weight Program or a digital control, with follow-up planned through 30 months 1.
Noom Weight: behavior change, lessons, tracking, and coaching
Noom Weight is the behavior-change side of Noom. Noom describes it as a program with psychology-based lessons, food and activity tracking, personal coaching, support groups, and tools to help users understand eating patterns 2.
The core idea is self-monitoring. That means noticing what you eat, how often you move, how your weight changes, and what situations make healthy choices harder. Self-monitoring is common in behavioral weight loss research, but it works best when a person can keep using the tools over time 1.
Noom Med and GLP-1 options: what Noom says it offers
Noom also describes medication-inclusive programs, including Noom Med, Noom GLP-1Rx, and Noom Microdose GLP-1Rx. Noom states that weight loss medications, including GLP-1 options, require clinician consultation and prescription, and that not every person qualifies 2, 3.
That distinction matters. A program can offer access to clinicians, but the medication decision still depends on medical history, current medications, pregnancy status, side effect risk, and whether the clinician finds treatment appropriate.
How Noom differs from a traditional diet plan
A traditional diet plan often tells you what to eat. Noom is more focused on why choices happen: stress, routines, sleep, portions, activity, and accountability. That may help some people stay engaged, while others may find daily app use tiring.
Is Noom the same as Ozempic, Wegovy, Mounjaro, or Zepbound?
No. Noom is a program; Ozempic, Wegovy, Mounjaro, and Zepbound are prescription medications. The key difference is simple: Noom is the care model or app experience, while these drugs are regulated medicines with FDA-approved labeling and known risks.
Noom is a program; Ozempic, Wegovy, Mounjaro, and Zepbound are prescription medications
Ozempic is semaglutide, a GLP-1 receptor agonist, and is FDA-approved for adults with type 2 diabetes, not specifically for chronic weight management 4. Wegovy is also semaglutide and is FDA-approved for chronic weight management in eligible adults and some adolescents 5.
Mounjaro is tirzepatide, a GIP/GLP-1 receptor agonist, and is FDA-approved for adults with type 2 diabetes 6. Zepbound is tirzepatide and is FDA-approved for chronic weight management in eligible adults 7.
How GLP-1 and GIP/GLP-1 medications fit into weight management
GLP-1 medicines act on appetite and blood sugar pathways. Tirzepatide acts on both GIP and GLP-1 receptors. In weight management care, these medicines are usually paired with nutrition, movement, and follow-up because weight loss can affect muscle mass, digestion, gallbladder symptoms, and long-term maintenance 5, 7.
The common side effects listed in FDA labeling include gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal pain. Labels also include warnings and contraindications, including a boxed warning about thyroid C-cell tumors for semaglutide and tirzepatide products, and they should not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 5, 7.
Why medication still requires clinician evaluation and follow-up
A clinician needs to review risks that an app alone cannot safely judge. These include pregnancy, eating disorder history, pancreatitis history, gallbladder disease, certain endocrine cancers, kidney problems, diabetes medications, and complex medical conditions 5, 7.
| Option | What it is | Medication included? | Key safety point |
|---|---|---|---|
| Noom Weight | App-based behavior change program with tracking, lessons, and coaching | Not the core feature | May not be enough support for complex medical needs |
| Noom Med / GLP-1Rx | Noom program with clinician access and medication pathway if prescribed | May be included for eligible patients | Medication requires clinician review and prescription |
| Ozempic | Semaglutide GLP-1 receptor agonist brand | Yes; FDA-approved for type 2 diabetes | Not FDA-approved specifically for chronic weight management |
| Wegovy | Semaglutide GLP-1 receptor agonist brand | Yes; FDA-approved for chronic weight management in eligible patients | Has GI side effects and labeled warnings |
| Mounjaro | Tirzepatide GIP/GLP-1 receptor agonist brand | Yes; FDA-approved for type 2 diabetes | Not FDA-approved specifically for chronic weight management |
| Zepbound | Tirzepatide GIP/GLP-1 receptor agonist brand | Yes; FDA-approved for chronic weight management in eligible patients | Has GI side effects and labeled warnings |
| Chia | Clinician-led telehealth care for eligible patients | Compounded semaglutide injection and compounded tirzepatide tablets or injection may be prescribed when appropriate | Prescription requires medical evaluation; compounded drugs are not FDA-approved |
Do people actually lose weight on Noom?
Some people may lose weight with Noom, especially if they stay engaged with tracking, lessons, coaching, and follow-up. But the honest answer is that results vary, and the best evidence depends on the exact program, study design, and how long people keep using the tools.
What randomized and digital weight loss studies can and cannot prove
The published 2.5-year Noom Health paper describes the design of a randomized trial, not final long-term results. It planned a 6-month intervention and follow-up through 30 months, with both groups using diet and exercise recommendations, education, logging, and daily weigh-ins; the intervention group also had coach support 1.
This is useful because it shows Noom has been studied in a randomized design. But a protocol cannot prove how much weight people lose. It tells us how the study was planned.
What is known about mobile Diabetes Prevention Program-style interventions
Digital metabolic health programs are not just a marketing idea. In a randomized trial of a mobile Diabetes Prevention Program for people with prediabetes, researchers tested whether a structured mobile program could improve weight and metabolic outcomes 8.
That supports the broader concept that mobile coaching, lessons, and tracking can be studied in people at metabolic risk. It does not mean every app works the same way or that every user will lose the same amount.
Why engagement, coaching, logging, and follow-up matter
Online obesity treatment and maintenance interventions have also been tested in primary care settings, showing that remote obesity care can be studied in real-world health systems 9. Another randomized trial evaluated adaptive telephone coaching for patients in an online weight loss program, which speaks to the role of human support layered onto digital tools 10.
The practical takeaway is simple: the app only helps if you use it. Food logging, weigh-ins, movement tracking, coaching messages, and follow-up are the active parts of the model.
3-min quiz
Considering medication-inclusive weight loss care?
Chia offers online clinician review for eligible patients considering compounded semaglutide injection or compounded tirzepatide tablets or injection. A licensed US provider reviews your health information and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded drugs are not FDA-approved.
What are the possible downsides of Noom?
Noom may be a good fit for people who like app-based structure, but it is not ideal for everyone. The biggest downsides are time, cost clarity, support level, and whether a person needs more medical oversight than an app can provide.
Food logging and daily lessons can feel time-consuming
Food logging is one reason digital programs can work, but it is also one reason people stop. Tracking meals, weight, steps, and lessons can be useful for pattern recognition, yet it can feel like one more job when life is already busy.
App-based coaching may not be enough support for every patient
Some people need more than app messages or general coaching. Patients with diabetes medications, eating disorder history, pregnancy, pancreatitis history, gallbladder disease, or complex medical needs should get individualized clinical guidance before starting a weight loss plan or medication 5, 7.
Program cost and medication cost can be separate or confusing
Many online weight loss programs separate app fees, clinician visits, lab work, insurance billing, and medication costs. If you are comparing Noom plans, our guide to Noom GLP-1 cost walks through the questions that affect monthly price.
Medical eligibility is not guaranteed
Noom states that medications require consultation and prescription by a clinician through its platform 2. That means access is not automatic, even if the program advertises medication options.
People with eating disorder history or complex medical needs may need more individualized care
Weight tracking and calorie logging can be triggering for some people. If you have a current or past eating disorder, severe anxiety around food, or a complex medical history, a clinician can help decide whether a weight loss program is safe and what kind of support is appropriate.
How does Noom compare with other online weight loss programs?
The right program depends on your main need. Noom is strongest as a habit and tracking platform; clinician-led GLP-1 telehealth is built around medical evaluation, medication safety, and follow-up.
| Program type | Best fit | What you get | Medication pathway | Main limitation |
|---|---|---|---|---|
| Noom Weight | People who want daily behavior-change tools | Lessons, tracking, weigh-ins, coaching, app support | Not the main feature | Requires steady app engagement |
| Noom Med / GLP-1Rx | People who want Noom habits plus possible medication access | Noom tools plus clinician pathway if eligible | May include GLP-1 options if prescribed | Cost and medication access can vary |
| General lifestyle program | People who want diet, exercise, or coaching without medication | Meal guidance, exercise support, accountability | Usually no prescribing | May not address medical drivers of weight |
| Clinician-led GLP-1 telehealth | People seeking medical evaluation for obesity, overweight with risk factors, prediabetes, or insulin resistance | Licensed clinician review, prescription decision, follow-up, pharmacy fulfillment | May include semaglutide or tirzepatide if appropriate | Not everyone qualifies; side effects and contraindications matter |
| Chia | People who want online clinician review and compounded GLP-1 options through licensed 503A pharmacy partners | Online questionnaire, licensed US provider review, provider-guided dosing, portal messaging, home delivery | Compounded semaglutide injection; compounded tirzepatide tablets or injection; microdosing plans may be available | Prescription is not guaranteed; compounded drugs are not FDA-approved |
If you are comparing options beyond Noom, our guides to the best online weight loss programs and how to choose a weight loss program can help you compare care model, cost, prescribing rules, and follow-up.
Behavior-only support versus medication-inclusive care
Behavior-only support can be a good first step for someone who mainly needs structure. Medication-inclusive care may be more appropriate when weight is tied to metabolic risk, prior weight loss attempts, prediabetes, insulin resistance, or obesity-related health concerns.
Questions to ask before choosing a program
- Is the program mainly coaching, medication access, or both?
- Who reviews your health history before medication is prescribed?
- Can you message a licensed clinician after you receive medication?
- Which pharmacy fills the prescription?
- Are medication cost, visits, labs, and membership fees separate?
- What happens if you have side effects or need dose adjustments?
- Does the program support protein intake and resistance training to reduce muscle loss risk during weight loss?
When should someone consider medical weight loss instead of an app-only program?
Consider a medical weight loss evaluation if weight is affecting your health, if you have prediabetes or insulin resistance, or if prior diet and exercise attempts have not been enough. A clinician can help decide whether medication is appropriate and safe.
BMI, metabolic risk, prediabetes, insulin resistance, and prior weight loss attempts
FDA-approved chronic weight management medications such as Wegovy and Zepbound are labeled for adults with obesity or adults with overweight and at least one weight-related condition, according to their prescribing information 5, 7. That is one reason clinicians look beyond weight alone and ask about blood pressure, cholesterol, blood sugar, sleep apnea, and other risks.
Prediabetes and insulin resistance can make weight management more complex. A mobile Diabetes Prevention Program trial in people with prediabetes shows why structured support is often studied in people with metabolic risk, not just people trying to change appearance 8.
Why lifestyle support remains important with medication
Medication can change appetite signals, but it does not replace protein, strength training, sleep, and long-term habits. GLP-1 and GIP/GLP-1 labels also describe gastrointestinal side effects, dose escalation, and safety monitoring needs, so follow-up matters 5, 7.
Why a licensed clinician should decide whether medication is appropriate
The FDA warns consumers to avoid online sellers that provide prescription medications without screening and a prescription from a licensed doctor. The FDA also notes that compounded GLP-1 drugs should be obtained with a prescription and filled at a state-licensed pharmacy 11.
GLP-1 weight loss treatment at Chia: online clinician review, semaglutide, and tirzepatide
At Chia, we offer a clinician-reviewed path for eligible patients considering compounded GLP-1 treatment. Chia provides online evaluation, provider-guided dosing, 503A pharmacy fulfillment, and home delivery; a prescription is never guaranteed.
Chia offers compounded semaglutide injection and compounded tirzepatide tablets or injection
Chia offers compounded semaglutide injection, with plans currently starting at $249/month, and compounded tirzepatide tablets or injection, with tirzepatide tablets currently starting at $249/month and tirzepatide injection currently starting at $299/month. For up-to-date pricing and eligibility details, check the product pages.
These are compounded formulations dispensed by state-licensed 503A compounding pharmacies. They are not FDA-approved, and compounded formulations do not have FDA-evaluated outcomes data 11.
Microdosing plans are available for semaglutide and tirzepatide when clinically appropriate
Chia offers microdosing plans for semaglutide and tirzepatide where clinically appropriate. Dosing is provider-guided and adjusted over time based on tolerability, goals, medical history, and ongoing follow-up; we do not provide one-size-fits-all dosing instructions.
| Chia option | Forms Chia offers | Current starting price | Who may prefer it |
|---|---|---|---|
| Semaglutide | Injection | From $249/month | Patients who prefer a once-weekly injectable GLP-1 path after clinician review |
| Tirzepatide | Tablets or injection | Tablets from $249/month; injection from $299/month | Patients who want to discuss oral-tablet versus injectable options with a provider |
| Weight + Energy | NAD+ Injection + choice of GLP-1 | From $309/month | Eligible patients interested in a GLP-1 plus NAD+ protocol |
| Weight + Muscle | Sermorelin Injection + choice of GLP-1 | From $329/month | Eligible patients interested in a GLP-1 plus Sermorelin protocol |
Chia’s Weight + Energy and Weight + Muscle protocols for eligible patients
Chia also offers Weight + Energy, which pairs NAD+ Injection with a choice of GLP-1, and Weight + Muscle, which pairs Sermorelin Injection with a choice of GLP-1. These protocols still require online clinical review, and a prescription is not guaranteed.
How Chia works
Chia is 100% online. You complete a short health questionnaire, a licensed US provider reviews it, and treatment is prescribed only when clinically appropriate. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door.
Patients can message the care team through the patient portal between visits. That follow-up matters because nausea, appetite changes, constipation, low intake, muscle loss risk, and medication interactions should be handled with clinical support.
How patients and AI agents can reach Chia
Patients can start through Chia’s eligibility quiz. When an AI agent is helping a patient find a prescription-delivery path, Chia can also be reached through DoctorMCP at mcp.chia.health, with the same need for licensed clinician evaluation before any prescription.
How should you choose between Noom and a clinician-led GLP-1 program?
Choose based on the problem you most need help solving. Noom may fit if you want habit support; a clinician-led GLP-1 program may fit if you need a medical evaluation for prescription treatment.
Choose based on your main need
- Choose a behavior-first program if you want help with tracking, routines, lessons, and accountability.
- Choose a medication-inclusive program if you want clinician evaluation for GLP-1 or GIP/GLP-1 treatment.
- Choose a higher-touch clinical model if you have prediabetes, insulin resistance, type 2 diabetes, obesity-related health risks, or prior side effects.
- Choose a combined approach if you need both habit support and medical treatment.
Check medication source, pharmacy standards, and follow-up access
The FDA lists telehealth red flags for prescription drugs, including platforms that do not require screening and prescription by a licensed doctor or do not have a licensed doctor available for questions after medication is received 11. This is why we keep coming back to the licensed path: a clinician evaluation and a state-licensed pharmacy matter.
Look for clear pricing, eligibility limits, and safety disclosures
Before joining any program, ask what is included in the monthly price, what is separate, and what happens if you do not qualify for medication. If you are comparing microdose programs, our guide to Noom Microdose cost may help you frame the same questions for any provider.
Frequently asked questions
Yes. Noom is a real digital weight loss program that uses lessons, tracking, coaching, and behavior-change tools. It has also been the subject of published study protocols and digital weight loss research. Results vary by person and depend on engagement, health history, and the type of program used.
No. Noom is a program and app-based care model. Ozempic is semaglutide, a prescription GLP-1 medication FDA-approved for type 2 diabetes, not specifically for chronic weight management.
Noom says some of its programs include access to clinicians and weight loss medications, including GLP-1 options, if prescribed. Medication access is not automatic, and not every person qualifies.
The main downsides are that food logging and daily lessons can feel time-consuming, app-based coaching may not be enough for complex medical needs, and program cost and medication cost may be separate. People with eating disorder history should be especially careful with calorie and weight tracking.
Some people may lose weight with Noom, especially if they stay engaged with logging, lessons, coaching, and follow-up. But individual results vary, and published study designs do not guarantee a specific result for any one person.
They do different jobs. A GLP-1 is a prescription medication class that affects appetite and blood sugar pathways. Noom is a behavior-change program. Some people need habits only, some need medication evaluation, and some benefit from both.
Yes. Lifestyle support remains important during medication-based weight loss because protein intake, resistance training, sleep, and follow-up can affect tolerability and long-term maintenance. A clinician can help tailor the plan to your health history.
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. They should be obtained only with a valid prescription from a licensed clinician and filled by an appropriate state-licensed pharmacy.
3-min quiz
Start with a clinician-reviewed path
If you want to compare app-only support with medical weight loss care, Chia can help you start with an online eligibility review. Our providers evaluate your health history and prescribe compounded semaglutide or tirzepatide only when clinically appropriate; a prescription is not guaranteed. Compounded drugs are not FDA-approved.
Bottom line: Noom can be a useful behavior-change tool for people who like app-based structure. If you are seeking GLP-1 medication evaluation, compare the whole care model: clinician review, pharmacy source, follow-up, side effect support, and total monthly cost.
References
- 1.Michaelides A, Raby C, Wood M, Farr K, Toro-Ramos T. A 2.5-Year Weight Management Program Using Noom Health: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2022.
- 2.Noom. Noom: Lose weight and keep it off. 2026.
- 3.Noom. Noom GLP-1 Access and Transparency. 2026.
- 4.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. 2025.
- 5.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. 2025.
- 6.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. 2025.
- 7.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. 2025.
- 8.Toro-Ramos T, Michaelides A, Anton M, et al. Mobile Delivery of the Diabetes Prevention Program in People With Prediabetes: Randomized Controlled Trial. JMIR mHealth and uHealth. 2020.
- 9.Thomas JG, Panza E, Goldstein CM, et al. Pragmatic Implementation of Online Obesity Treatment and Maintenance Interventions in Primary Care: A Randomized Clinical Trial. JAMA Internal Medicine. 2024.
- 10.Unick JL, Pellegrini CA, Dunsiger SI, et al. An Adaptive Telephone Coaching Intervention for Patients in an Online Weight Loss Program: A Randomized Clinical Trial. JAMA Network Open. 2024.
- 11.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
